"Maximize the worth"?!!!! You must be kidding?!!!! The two have virtually killed the company, reducing it to a just one-product company and have failed so far to earn any noticeable respect from the FDA. And, OPC1 trial approval by the FDA clearly shows that these two bozos were out of their mind to dispose off the stem cell assets dirt cheap!! Note that your dreams do not make the future; it's the history full of facts that counts.
What is the weightage of Tefferi's disturbing dislike and public criticism of Jakafi inhibitors? Is it all ignored by the FDA? What does Tefferi has to say about Pacritinib?
Excellent summary; and, it's a realistic assessment. Thanks for that End!
My conclusion is that Geron board needs to pursue accountability investigation for both Huh and Scarlett. With these two at the helm, I only see more frustrations for retail shareholders. And, they have done a lousy job at adding to shareholder value if you keep in mind the fact that neither of the two had any input in development of Imetelstat; and, despite putting all their eggs in the Imetelstat basket, they kept screwing up its licensing process. I will single out these two bozos who squeezed hefty compensation from this resource-poor company and not justifying their remuneration. We, the shareholders, not only lost our hundreds of millions in investment for stemcells patents and rights; but have lost potential share value(which was considered to be in 40s and 50s down to 10s) through their repeated screw ups of solid-tumor and hematolgical trials for Imetelstat, the only product the company owns now These bozos now are primarily riding on the success brought about by Tefferi. And, yet, to my dismay, many on this board love them!! What an irony!!
My vote is unfavorable and it should be known to all who have been reading my posts for at least the last several weeks I have also given my views in the posts occasionally. Please treat those as sincere. Thanks.
Guys, if she is what she claimed, she certainly will respond to these posts. None of you have to speak for or against her!! Just be patient and wait in case she is away to respond.
that Scarlett and Huh are the right guys to take this company to glory? Please vote through Up Thumb for favorable vote and vice versa for your unfavorable vote. If you have a favorable vote, please do not hesitate to give your reasons briefly. Please be honest and take this survey seriously and to the benefit of all who visit this board Thanks.
Perhaps Irish got frustrated with Geron and sold off her Geron holdings in case the two bozos sell the company and its BT product cheap through their WS buddies!!
There are idiots in the FDA and also it's full of agents of vested interests. If Jakafi with all its side effects much more severe than those found with use of Imetelstat for MF is allowed rampant use by this agency, you should know who controls the FDA. In our capitalistic system, shouldn't power of money rule?!!!! The problem with Geron is that it's headed by two bozos who act like a misguided missile.
Why did you miss the offer from Maine who wanted to sell all his holdings in ASTY because he trusts Scarlett-Huh team so much he hated stem-cells and West-Okarma team!!!
Wall Street has more confidence in West-Okarma team than inept Huh-Scarlett team!!!
It's all reflective of inability and ineptness of Scarlett and Huh to lead Geron.!! I do not see any other reason!
We're in a world where there is cut-throat competition. I am sure if Imetelstat brought CRs and PRs, as shown by none other than the world-famous and respected outfit like Mayo, there will be at least a few large pharmas who will be coming to the help. Scarlett and Huh are just two frustratingly inept guys who can't bring that out quickly!!!
End, I am seeing your other side which I never had before!! To come to a conclusion about others and advise them that they should divest from a company they think have a BT product but has lousy management is a cheap shot if you yourself like the management for whatever reason you have in your mind.
I am heavily invested in Geron also; but, I have stayed with it not because I also think it has an inept management but it has a valuable product. Geron management can be changed or corrected but no body is going to take away the CRs and PRs Imetelstat has attained through the study by none other than the world famous and highly reputed Mayo. And, Mayo also has indicated that Imetelstat may have a strong potential for multiple oncologic applications.
But you suggest that we should sell our Geron holding only because we do not trust the management? That is the advice fit for a trader! Aren't you an investor too? Or are you just such a trader? I, personally, do not believe that you are trader and believe that you are a wise short-to-middle term investor who hops in and out occasionally to take profits; but, that's not what every investor wants to do, especially if one is a long-term investor who doesn't want to hop in and out. And, to criticize Geron management on this board is not a sin, neither does it make one a bad investor if he does so, especially if the company owns a BT drug!!! In fact, it's an issue worthy of open discussion.
Guys, just restrict your posts from personal attacks and to constructive ideas, suggestions, discussions and your own thoughts to make this board worthy of a visit, please!
End, you're making good credible points. Sure, large pharmas follow regulations much more closely and have apparently learned how to deal with the FDA. That also means that the Geron management did screw up something to face the long hold. If so, transfer from Mayo to Geron may be a disadvantage unless Geron partners with a large pharma. However, the board/commissioners that advises the FDA do consist of representatatives from large pharmas and, therefore, you can't completely rule out second-class status of start ups like Geron, especially if their product challenges that of a large pharma whose agent is in the board, isn't it.
End, let me ask you one simple question: How did these FDA requirements apply to licensing the Jakafi inhibitor? The FDA has certainly a complex set of rules governing licensing of INDs; but, the question is how these rules have been implemented for INDs by large pharmas v/s those for small outfits like Geron's, especially if it's drug beats that licensed for a large pharma!! Have you investigated that?!